We report the case of a woman with HER2-positive metastatic breast cancer who achieved prolonged complete remission of multiple liver metastases after treatment with weekly trastuzumab plus paclitaxel but relapsed in the brain soon after stopping trastuzumab maintenance therapy which had been prosecuted for almost three years. In the absence of randomized trials, the optimal duration of trastuzumab administration after achieving complete remission of metastatic breast cancer remains questionable.
MartyM., CognettiF., MaraninchiD., SnyderR., MauriacL., Tubiana-HulinM., ChanS., GrimesD., AntónA., LluchA., KennedyJ., O'ByrneK., ConteP.F., GreenM., WardC., MayneK., ExtraJ.M.: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.J Clin Oncol, 23: 4247–4250, 2005
2.
SlamonD.J., Leyland-JonesB., ShakS., FuchsH., PatonV., BajamondeA., FlemingT., EiermannW., WolterJ., PegramM., BaselgaJ., NortonL.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2.N Engl J Med, 344: 783–792, 2001.
3.
PusztaiL., EstevaF.J.: Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer.Cancer Invest, 24: 187–191, 2006.
4.
TomaoF., MieleE., SpinelliG.P., RussilloM., La FerlaG., TomaoS.: Trastuzumab in metastatic breast cancer.Eur J Gynaecol Oncol, 27: 247–249, 2006.
5.
ClaytonA.J., DansonS., JollyS., RyderW.D., BurtP.A., StewartA.L., WilkinsonP.M., WelchR.S., MageeB., WilsonG., HowellA., WardleyA.M.: Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.Br J Cancer, 91: 639–643, 2004.
6.
BendellJ.C., DomchekS.M., BursteinH.J., HarrisL., YoungerJ., KuterI., BunnellC., RueM., GelmanR., WinerE.: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.Cancer, 97: 2972–2977, 2003.
7.
DuchnowskaR., SzczylikC.: Central nervous system metastases in breast cancer patients administered trastuzumab.Cancer Treat Rev, 31: 312–318, 2005.
8.
Puente VazquezJ., Lopez-Tarruella CoboS., Garcia-SaenzJ.A., Casado HerraezA., Moreno AntonF., Sampedro GimenoT., Bueno MuinoC., Grande PulidoE., Martin JimenezM., Diaz-RubioE.: Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies.Clin Transl Oncol, 8: 50–53, 2006.
9.
KirschD.G., LoefflerJ.S.: Brain metastases in patients with breast cancer: new horizons.Clin Breast Cancer, 6: 115–124, 2005.
